In conclusion, (ruxolitinib + ERBB1/2/4 inhibitors) treatment kills genetically diverse tumor cells by facilitating autophagosome and autolysosome formation over the course of 6–12 h through inactivation of HSP90/HSP70-mTOR and activation of eIF2α-Beclin1 pathways. Here, EGFR is linked to neoplasm.